Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.
We describe a 34-year-old male patient suffering from familial Mediterranean fever and experiencing an increase in both the frequency and severity of disease attacks, suggesting resistance to chronic treatment with colchicine. Since no alternative treatment is established, anakinra, an interleukin-1 receptor antagonist, was administered, not daily, as it has been previously reported, but only during crises, with successful outcome.
Mitroulis
I
I
First Division of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Papadopoulos
V P
VP
Konstantinidis
T
T
Ritis
K
K
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003078:Colchicine / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D010505:Familial Mediterranean Fever / Q000188:drug therapy*; D006074:Gout Suppressants / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male
D018501:Antirheumatic Agents; D006074:Gout Suppressants; D053590:Interleukin 1 Receptor Antagonist Protein; D003078:Colchicine